ReGen Theranostics

ReGen Theranostics is a biotechnology company focused on advancing regenerative medicine through the use of induced pluripotent stem cell (iPSC) technology. Spun out of the Mayo Clinic, the company specializes in developing cell-based therapies and drug discovery platforms, with a primary emphasis on cardiovascular conditions such as heart failure and congenital heart defects. Their approach involves reprogramming patient-specific cells to create functional tissues for therapeutic transplantation and disease modeling. By leveraging high-throughput screening and advanced bioengineering, ReGen Theranostics aims to provide personalized treatments for complex diseases that currently lack effective cures. The company's platform serves as a bridge between academic research and the commercialization of next-generation regenerative biotherapeutics.